REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion. 2019

Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
From the Mayo Center for Sleep Medicine, Departments of Neurology, and Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.

To determine whether REM sleep without atonia (RSWA) during polysomnography (PSG) predicts phenoconversion in patients with idiopathic REM sleep behavior disorder (iRBD), a prodromal feature of a neurodegenerative disease. We analyzed RSWA in 60 patients with iRBD, including manual phasic, tonic, and any muscle activity in the submentalis and anterior tibialis muscles and the automated REM atonia index in the submentals. We identified patients who developed parkinsonism or mild cognitive impairment (MCI) during at least 3 years of follow-up after PSG. Kaplan-Meier analysis was performed and receiver operator curves were calculated to determine RSWA cutoffs predicting faster phenoconversion. Twenty-six (43%) patients developed parkinsonism (n = 17) or MCI (n = 9). Phenoconverters were older at iRBD diagnosis (p = 0.02). Median time to phenoconversion was 3.9 ± 2.5 years. iRBD phenoconverters had significantly more RSWA at diagnosis. Phenoconversion risk from iRBD diagnosis was 20% and 35% at 3 and 5 years, respectively, with greater risk in patients with iRBD with >46.4% any combined RSWA, which increased further to 30% and 55% at 3 and 5 years for patients >65 years of age at diagnosis. Patients with iRBD with higher amounts of polysomnographic RSWA had a greater risk of developing Parkinson disease or MCI. Patients with older age and higher RSWA amounts had more rapid phenoconversion than younger patients with RBD. Our study suggests that RSWA is a potential biomarker for risk stratification of iRBD phenoconversion that could facilitate prognostication for patients with iRBD. This study provides Class II evidence that for patients with iRBD, increased RSWA correlates with increased risk for developing parkinsonism or MCI.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009123 Muscle Hypotonia A diminution of the skeletal muscle tone marked by a diminished resistance to passive stretching. Flaccid Muscle Tone,Hypotonia,Decreased Muscle Tone,Floppy Muscles,Hypomyotonia,Hypotony, Muscle,Muscle Flaccidity,Muscle Tone Atonic,Muscle Tone Poor,Muscular Flaccidity,Muscular Hypotonia,Neonatal Hypotonia,Unilateral Hypotonia,Flaccidity, Muscle,Flaccidity, Muscular,Floppy Muscle,Hypotonia, Muscle,Hypotonia, Muscular,Hypotonia, Neonatal,Hypotonia, Unilateral,Hypotonias, Neonatal,Hypotonias, Unilateral,Muscle Hypotony,Muscle Tone Atonics,Muscle Tone, Decreased,Muscle Tone, Flaccid,Muscle, Floppy,Muscles, Floppy,Muscular Flaccidities,Neonatal Hypotonias,Tone Atonic, Muscle,Tone Poor, Muscle
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
June 2020, Clinical autonomic research : official journal of the Clinical Autonomic Research Society,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
May 2022, Movement disorders : official journal of the Movement Disorder Society,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
September 2019, Sleep,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
April 2021, Movement disorders : official journal of the Movement Disorder Society,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
January 2022, Journal of Parkinson's disease,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
October 2021, Journal of clinical medicine,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
September 2009, Sleep,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
December 2022, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
May 2017, Sleep,
Stuart J McCarter, and David J Sandness, and Allison R McCarter, and John C Feemster, and Luke N Teigen, and Paul C Timm, and Bradley F Boeve, and Michael H Silber, and Erik K St Louis
January 2010, Neurology,
Copied contents to your clipboard!